Perseus’s Offer for OreCorp Unconditional and Best and Final

Written by Customer Service on April 7, 2024. Posted in Public Companies.

perth, April 08, 2024 (GLOBE NEWSWIRE) — PERSEUS OFFER UNCONDITIONAL AND BEST AND FINAL Perth, Western Australia/ April 8, 2024/Perseus Mining Limited (ASX/TSX: PRU) (Perseus or PRU) refers to its off-market takeover bid under Chapter 6 of the Australian Corporations Act for all the current and to be issued ordinary shares in OreCorp Limited (ASX: ORR) (OreCorp or ORR) (Offer).1 As at April 5, 2024, Perseus has a relevant interest in 239,542,398 OreCorp Shares representing 51.03% of OreCorp Shares on issue. As such, Perseus has declared that the Offer is now: unconditional; and best and final in the absence of a competing proposal. OreCorp Shareholders should Accept the Offer now in respect of Your OreCorp Shares. Proposed OreCorp Board Changes Perseus refers to OreCorp’s announcement today noting that OreCorp is actively working...

Change to Perseus’s Senior Management Team

Written by Customer Service on April 7, 2024. Posted in Public Companies.

perth, April 08, 2024 (GLOBE NEWSWIRE) — CHANGE TO PERSEUS’S SENIOR MANAGEMENT TEAM Perth, Western Australia/April 8, 2024/Perseus Mining Limited (ASX/TSX: PRU) wishes to advise that its Chief Operating Officer (COO), Mr. David Schummer, has advised that he will resign from the Company with effect from September 30, 2024, to pursue new employment opportunities located closer to his family in North America. Mr. Schummer has agreed to remain in his role with Perseus until the end of September to manage a number of strategic work streams that are currently underway at the mine sites and to assist with the smooth transition to his successor. The process to select and appoint a new COO will commence immediately with consideration being given to both internal and external candidates for the role. Perseus’s Chairman and CEO Jeff Quartermaine...

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

Written by Customer Service on April 7, 2024. Posted in Public Companies.

Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R mutation, a setting characterized by shorter duration of response to osimertinib BDTX-1535 profile differentiated as the most advanced fourth-generation oral TKI in clinical development addressing the full spectrum of classical, non-classical, and C797S resistance EGFR mutations CAMBRIDGE, Mass., April 07, 2024 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, presented real-world evidence of the evolving epidermal growth factor receptor (EGFR) mutation landscape in non-small cell...

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

Written by Customer Service on April 7, 2024. Posted in Public Companies.

RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in evaluable patients SAN DIEGO, April 07, 2024 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the presentation of interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the treatment of skin cancers in patients who have had solid organ or hematopoietic cell transplants, by Michael R. Midgen, M.D., of the University of Texas MD Anderson Cancer Center during an oral session at the AACR 2024 Annual Meeting in San Diego. The results were initially presented late last year at the 38th Annual Meeting of the Society...

iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024

Written by Customer Service on April 7, 2024. Posted in Public Companies.

WATERTOWN, Mass. and GOSSELIES, Belgium, April 07, 2024 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced a poster presentation of preclinical data on EOS-984, a potential first-in-class small molecule inhibitor targeting the equilibrative nucleoside transporter 1 (ENT1) in oncology, at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, California. Based on the Company’s discovery and characterization of ENT1 in adenosine-mediated immunosuppression, this novel mechanism allows for the intracellular accumulation of adenosine, which then suppresses proliferation and effector function of T cells in the...

Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma

Written by Customer Service on April 7, 2024. Posted in Public Companies.

Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) TARRYTOWN, N.Y., April 07, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the oral plenary session presentation of positive pivotal data from the Phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory (R/R) multiple myeloma (MM) at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego. Linvoseltamab is an investigational bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing. “The presentation of these pivotal results in an oral plenary session at AACR recognizes...

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Written by Customer Service on April 7, 2024. Posted in Public Companies.

– Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo – – NEXLETOL Demonstrated Clinical Benefit in Historically Underrepresented Groups: Women and Hispanic/Latinx Patients With and Without Cardiovascular Disease (CVD) – – CLEAR Outcomes Sets New Standards for Diversity and Inclusion with Enrollment of 48% Women and 17% Hispanic/Latinx Patients – ANN ARBOR, Mich., April 07, 2024 (GLOBE NEWSWIRE) — Esperion (Nasdaq: ESPR) today announced the presentation of results from three pre-specified subgroups from CLEAR Outcomes at the 2024 American College of Cardiology’s Annual Scientific Sessions (ACC.24): women, Hispanic/Latinx, and patients with obesity. These results align with the American College of Cardiology’s robust diversity, equity and inclusion...

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

Written by Customer Service on April 7, 2024. Posted in Public Companies.

Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell responses up to three years and delayed tumor recurrence in patients with resected pancreatic ductal adenocarcinoma (“PDAC”) A randomized Phase 2 clinical trial with autogene cevumeran in patients with resected PDAC is currently enrolling patients at clinical trial sites in the United States, with additional sites planned to open globally The medical need in PDAC is high with a 5-year overall survival rate of only 8-10%1,2, high recurrence rates after surgery at nearly 80%3 and limited treatment options Autogene cevumeran, jointly developed by BioNTech and Genentech Inc. (“Genentech”), a member of the Roche Group, is the lead candidate of BioNTech’s...

BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Written by Customer Service on April 7, 2024. Posted in Public Companies.

– In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression – The data demonstrate that targeting near-complete transthyretin (TTR) stabilization with acoramidis may enable cardiac remodeling and functional recovery in patients with ATTR-CM – These results are the first prospective, longitudinal evaluation of cardiac structure and function by CMR imaging in a double-blind, placebo-controlled, interventional study in ATTR-CM – The findings from this study build upon positive results from BridgeBio’s global ATTRibute-CM Phase 3 trial, wherein the primary endpoint was met (Win Ratio of 1.8) with a high statistical significance (p

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

Written by Customer Service on April 7, 2024. Posted in Public Companies.

SHANGHAI, China, April 07, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (“NMPA”) has approved the supplemental new drug application (“sNDA”) for toripalimab (product code: JS001) in combination with axitinib for the first-line treatment of patients with medium to high risk unresectable or metastatic renal cell carcinoma (“RCC”). This is the first approved immunotherapy for renal carcinoma in China. Renal carcinoma is the third most common malignancy of the urinary system globally, and RCC accounts for 80%~90% of all cases of renal carcinoma. There were approximately 77,000...

Day: April 7, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice